Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma Ltd. Ordinary Shares (NSRX)
Company Research
Source: GlobeNewswire
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with NS002 compared to 67% with EpiPen® NS002 was well-tolerated with no serious adverse events reported, and a pharmacodynamic response comparable to EpiPen® Full Phase 2 results expected by the end of first quarter of 2026; Pivotal study initiation planned for fourth quarter of 2026 TEL AVIV, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced positive interim results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The data demonstrated that NS002 achieved faster absor
Show less
Read more
Impact Snapshot
Event Time:
NSRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NSRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NSRX alerts
High impacting Nasus Pharma Ltd. Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NSRX
News
- Nasus Pharma CEO Issues 2025 Letter to ShareholdersGlobeNewswire
- Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial OfficerGlobeNewswire
- Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed [Yahoo! Finance]Yahoo! Finance
- Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant DosedGlobeNewswire
NSRX
Sec Filings
- 1/29/26 - Form 6-K
- 1/20/26 - Form 6-K
- 12/29/25 - Form 6-K
- NSRX's page on the SEC website